Tezepelumab, a human mAb anti-thymic stromal lymphopoietin (TSLP), enhances the efficacy of SCIT in cat-triggered allergic rhinitis patients and may promote tolerance after a 1-year course of treatment [41]. Here, TSLP is linked to allergic rhinitis.